At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 510 enrolled
Drug / intervention
Riboflavin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia
In Brief
A Phase 2 clinical trial evaluating Riboflavin and UVX light for Keratoconus and Post-Refractive Ectasia. Completed, enrolled 510 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconus, Post-Refractive Ectasia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionMay 2017
Study CompletionAug 2017
TodayJul 2026
First PostedJun 14, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 30, 2017
Study CompletionAug 30, 2017
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 16.1 years ago
Interventions
Riboflavindrug
Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX lightdevice
UVX 365 nm wavelength light source is applied with continued application of riboflavin.